Cyclo Therapeutics, Inc.

The rare lysosomal storage disorder Niemann-Pick disease type C (NPC) now has two approved therapies as the US Food and Drug Administration gave a thumbs-up to IntraBio Inc. ’s modified amino acid Aq

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Teams With Oblique On Antibody Di

Syndax Pharmaceuticals’ Revumenib PDUFA for NDA – First Review 26 September A new opportunity is opening up in a rare subset of patients with acute leukemia – those with KMT2A rearrangements. Synda

Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding